Search

Search Constraints

You searched for: Author/Creator Frémond, Marie-Louise

Search Results

1. Anti-MDA5 juvenile idiopathic inflammatory myopathy: a specific subgroup defined by differentially enhanced interferon-α signalling. (22nd November 2019)

2. Association between type I interferon pathway activation and clinical outcomes in rheumatic and musculoskeletal diseases: a systematic literature review informing EULAR points to consider. Issue 1 (7th March 2023)

3. Comment on: 'Aberrant tRNA processing causes an autoinflammatory syndrome responsive to TNF inhibitors' by Giannelou et al: mutations in TRNT1 result in a constitutive activation of type I interferon signalling. Issue 8 (1st August 2019)

4. Comment on: 'Aberrant tRNA processing causes an autoinflammatory syndrome responsive to TNF inhibitors' by Giannelou et al: mutations in TRNT1 result in a constitutive activation of type I interferon signalling. Issue 8 (1st June 2018)

6. Efficacy of JAK1/2 inhibition in the treatment of chilblain lupus due to TREX1 deficiency. Issue 3 (3rd March 2019)

7. Efficacy of JAK1/2 inhibition in the treatment of chilblain lupus due to TREX1 deficiency. Issue 3 (3rd October 2018)

9. JAK inhibitors are effective in a subset of patients with juvenile dermatomyositis: a monocentric retrospective study. (12th February 2021)

10. OP0107 HETEROZYGOUS MUTATIONS IN COPA ARE ASSOCIATED WITH ENHANCED TYPE I INTERFERON SIGNALLING. (June 2019)